Trials / Completed
CompletedNCT01109069
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
A Long-term Safety Study of Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 199 (actual)
- Sponsor
- Pharmacyclics LLC. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the long-term safety of a fixed-dose, daily regimen of PCI-32765 PO in subjects with B cell lymphoma or chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL).
Conditions
- B-cell Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Diffuse Well-differentiated Lymphocytic Lymphoma
- B Cell Lymphoma
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Non-Hodgkin's Lymphoma
- Waldenstrom Macroglobulinemia
- Burkitt Lymphoma
- B-Cell Diffuse Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PCI-32765 | Dose based on parent protocol |
Timeline
- Start date
- 2010-06-01
- Primary completion
- 2019-04-26
- Completion
- 2019-04-26
- First posted
- 2010-04-22
- Last updated
- 2020-05-27
- Results posted
- 2020-05-07
Locations
16 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01109069. Inclusion in this directory is not an endorsement.